“Behind-The-Counter” Drug Switches Must Tackle Restrictions On Use For Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.
You may also be interested in...
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
The questions FDA poses for a March 22-23 hearing indicate the agency is delving into greater detail than in its previous discussions of alternative routes to access pharmaceutical treatments. FDA says decisions would be made case by case, but refers to treating conditions including high cholesterol, high blood pressure, migraines and asthma.
Pharmacists See Challenges, Opportunities In Behind-The-Counter Class
Pharmacy trade groups welcome the possibility of a behind-the-counter class of drugs, but a pharmacy professor and former FDA Nonprescription Drugs Advisory Committee chairman cautions a third class could create more demand than pharmacists are able to manage
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.